Isabella Cueto, a renowned expert in chronic diseases, particularly autoimmune conditions and diseases of the liver, kidneys, and lungs, provides valuable insights and updates on some of the leading causes of death and disability in the medical field. Her focus on intriguing research, the promises and pitfalls of treatment, and strategies to combat the burden of disease is highly commendable.
In the latest edition of the AASLD in 30 Seconds newsletter, the American Association for the Study of Liver Diseases’s Liver Meeting concluded with a note of safe travels back home for all attendees, amidst possible travel disruptions due to a shutdown. Despite the chilly temperatures at the conference center, attendees found solace in “The Park” on the third floor, which bathed in sunlight and provided a cozy retreat for many.
One of the highlights of the conference was the presentation of data on primary biliary cholangitis (PBC), semaglutide, and a metabolic accelerator. In a late-breaking session, the results of the open-label extension of the phase 3 ELATIVE trial were shared, focusing on the long-term effects of elafibranor therapy in patients with PBC. Elafibranor, which received accelerated FDA approval as a second-line therapy for PBC, showed sustained improvements in biomarkers for bile flow and fibrosis markers in participants, suggesting a potential slowdown in disease progression. Additionally, improvements in symptoms like fatigue and itching were observed, with no new safety concerns reported. The ELATIVE extension trial continues to progress.
Unfortunately, the remainder of the article is exclusive to STAT+ subscribers, offering in-depth analysis, newsletters, premium events, and news alerts. To access the full content and stay updated on the latest developments in liver diseases and other chronic conditions, interested readers are encouraged to subscribe to STAT+.
In summary, Isabella Cueto’s dedication to shedding light on chronic diseases and the advancements in their treatment is invaluable. The insights shared at the AASLD Liver Meeting provide a glimpse into the ongoing efforts to improve the lives of patients affected by these debilitating conditions.
